CLEO Appoints First Key Opinion Leader to Support U.S. Market Entry
Dr Nicholas Lambrou, leading U.S. gynaecologic oncologist
Highlights
CLEO appoints its first U.S. Key Opinion Leader, Dr Nicholas Lambrou, a leading gynaecologic oncologist and surgical specialist
Dr Lambrou to support clinical advocacy, publication development, and presentation of CLEO’s technology at major U.S. scientific meetings
KOL engagement represents a key U.S. market entry activity as a part of CLEO’s commercialisation strategy for its Pre Surgical Ovarian Cancer Test.
MELBOURNE, AUSTRALIA, 19th November 2025: Ovarian Cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) is pleased to announce the appointment of leading U.S. gynaecologic oncologist, Dr Nicholas Lambrou, as the Company’s first Key Opinion Leader (KOL).
Dr Lambrou is a highly respected U.S. based surgeon, clinical advisor, and researcher with extensive expertise in oncology, gynaecologic surgery, and women’s health. Dr. Lambrou completed his residency at the Johns Hopkins Hospital and University. After completing fellowship at the University of Miami, Dr. Lambrou served as associate professor and has authored or co-authored multiple peer-reviewed publications, book chapters and editorship. He has participated in the latest clinical trials in the treatments of gynaecologic cancers and is actively recruiting patients for CLEO’s U.S. clinical trial. His appointment represents a major step in CLEO’s U.S. market entry strategy with respect to early-adopter engagement, and clinical advocacy.
Commenting on his KOL Appointment, Dr Nick Lambrou, said:
“I am thrilled to join CLEO at such a pivotal point in its journey. Backed by more than 15 years of rigorous scientific research, CLEO’s work has reached a point where it can now be translated into real clinical practice where it has the potential to make a profound difference. As a surgeon who confronts the diagnostic uncertainty around ovarian cancer every day, I see enormous value in a pre-surgical test that can bring greater accuracy, confidence, and clarity to women, doctors and gynaecologic oncologists. I look forward to working with the CLEO team to help introduce this innovation into the U.S. healthcare system and advance a new standard of care for women.”
Under the Agreement, Dr Lambrou will support the Company in the following activities:
Clinical and medical review of CLEO’s research, data, and publications
Advisory input on data interpretation, manuscript development, and presentation materials
Presentation of CLEO’s research findings at scientific meetings and congresses in the U.S.
Participation in CLEO’s Advisory Board and other strategic consultation activities.
This appointment strengthens CLEO’s execution pathway as the Company prepares for the launch of its Pre-Surgical Ovarian Cancer Test next year. Establishing a network of respected U.S. KOL’s is a core pillar of CLEO’s early-market engagement strategy, supporting clinical validation, awareness-building, and early adoption among specialist clinicians.
Dr Lambrou’s presence and influence within the U.S. healthcare ecosystem, particularly among gynaecologic oncologists, surgeons, and women’s health centres, will play a central role in CLEO’s market entry activities. His clinical expertise and visibility will help the Company accelerate introduction of its technology into the U.S. and provide independent, practice-based insights to support market education and uptake.
Commenting on the KOL Appointment, CLEO’s Chief Executive Officer, Dr Richard Allman, said:
“Appointing Dr Lambrou as our first KOL marks a meaningful milestone in our market-entry preparation. His clinical leadership, experience, and proximity to the U.S. market, being our largest commercial opportunity, will support CLEO’s staged execution strategy, ensuring our technology is introduced with the right clinical voices, scientific credibility, and pathways for early adoption.”
The Company expects to expand its KOL and advisory network as it moves through key development, regulatory, and commercialisation milestones.